Kinidin

Quick links to important sections

Kinidin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kinidin

Kinidin is a medication used to regulate the electrical activity of the heart. It contains the active substance Quinidine, a foundational drug in the management of specific heart rhythm disturbances.

Property Description
Active Ingredient Quinidine (Sulfate, Bisulfate, or Gluconate)
Form Oral tablets, extended-release tablets, injection solution
Pharmacological Class Class Ia Antiarrhythmic Agent
Common Use Stabilizing abnormal heart rhythms
Origin Naturally derived Cinchona alkaloid

What is Kinidin and How is it Classified?

Kinidin refers to a pharmaceutical product containing the potent active substance Quinidine, which functions as a rhythm regulator for the heart. Quinidine is explicitly categorized as a Class Ia Antiarrhythmic Agent within the Vaughan Williams classification system, a designation that is clinically recognized for its efficacy in altering cardiac conduction. This classification signifies its specific role in influencing the heart's electrical conduction system to stabilize the rhythm, often used in scenarios where the heart is beating too rapidly or irregularly.

Composition and Origin: Is Quinidine Natural or Synthetic?

The active ingredient Quinidine is historically notable as a naturally derived alkaloid, an organic compound originally isolated from the bark of the Cinchona tree. Quinidine is structurally a stereoisomer of the related alkaloid Quinine. Kinidin is provided as a single-ingredient medication, typically formulated using the salts Quinidine Sulfate or Quinidine Bisulfate, and is available in forms like standard oral tablets and extended-release tablets for ingestion. The availability of the extended-release form is a key differentiator, designed to provide sustained therapeutic levels necessary for rhythm maintenance.

High-Level Function: What Does Kinidin Achieve?

The general function of Kinidin is to electrically stabilize the heart, managing the rapid or chaotic electrical impulses that lead to rhythm disorders. As an established Class Ia antiarrhythmic, Quinidine works by modulating ion channels, primarily acting as a sodium channel blocker. By regulating these electrical signals, Kinidin provides a method for restoring and maintaining a regular, effective heart rhythm, a therapeutic goal crucial for patients experiencing cardiac electrical instability.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH StatPearls

What side effects are possible with Kinidin?

Possible Side Effects and Safety Information

The safety profile of Kinidin, which contains the active substance Quinidine, is documented through classifications that describe the frequency and nature of possible adverse reactions as defined in official regulatory labeling. These effects are formally grouped into categories based on the organ system affected.

The most frequently reported adverse reactions are classified as Very Common and are primarily Gastrointestinal Disorders. These include Diarrhea, Nausea, Vomiting, and Abdominal Pain. Other reactions are classified as Common, such as Tinnitus, Headache, and Blurred Vision, often associated with the syndrome known as Cinchonism, which is typically dose-related.


Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize the risk of Serious Adverse Reactions, particularly within the Cardiac Disorders class. These include the potential for Proarrhythmic Effects, such as the induction of severe ventricular arrhythmias like Torsade de Pointes and Ventricular Fibrillation. These serious events may occur relatively early in treatment and are often dose-dependent.

Less frequent but severe reactions affecting the Blood and Lymphatic System are also documented, including Thrombocytopenia and Agranulocytosis.

Official labeling defines Safety-Related Restrictions for specific patient groups. For example, careful monitoring and potential dose adjustment are advised in individuals with Renal Impairment or Hepatic Impairment. The use of the medicine is officially contraindicated in conditions such as existing high-degree A-V block (without a pacemaker) and in patients with a history of quinidine-induced thrombocytopenia.

Overdose and Emergency Response

Kinidin Overdose and When to Seek Help

The information below summarizes the official overdose profile for Kinidin (quinidine) and actions required in an emergency, as documented in authoritative regulatory sources.

Documented Overdose Presentations

Overdose often results in severe cardiotoxicity, which is the primary life-threatening concern. Initial symptoms may appear within 2 to 4 hours post-ingestion. These may include:

  • Cardiovascular: Irregular heartbeat (ventricular arrhythmias), severe low blood pressure (hypotension), and disturbances in cardiac conduction.
  • Central Nervous System (CNS): Confusion, headache, syncope, delirium, coma, or convulsions.
  • Sensory: Ringing in the ears (tinnitus) or loss of hearing, and blurred or changed vision.
  • Gastrointestinal: Diarrhea and vomiting.

Immediate Emergency Action

Immediate medical help is required in all cases of suspected overdose. The drug has a low toxic-to-therapeutic ratio, and toxic effects can progress rapidly. If the person has collapsed, is having trouble breathing, has had a seizure, or cannot be awakened, contact emergency services immediately.

Overdose Management Focus

Regulatory documentation highlights the need for continuous monitoring in an intensive care unit (ICU), focusing on the patient's ECG, blood pressure, and respiration. Management involves supportive treatment and the use of specific interventions, such as hypertonic sodium solutions, to counteract the severe cardiovascular toxicity.

Therapeutic Uses of Kinidin

Quick Facts

  • Management of irregular heart rhythms: Used to help sustain a stable heart rhythm.
  • Restoration of normal heart rhythm: May be utilized to convert atrial fibrillation or flutter to sinus rhythm.
  • Ventricular arrhythmias: Intended for the suppression of recurrent, documented ventricular arrhythmias.
  • Antimalarial use: Indicated for the management of Plasmodium falciparum malaria.

Kinidin (quinidine) is a prescription treatment primarily used to manage specific cardiac rhythm disturbances. The medication is an established therapeutic option that works to help the heart maintain a regular pattern. This is often initiated after other therapeutic measures have been found to be inadequate for control.

Kinidin is indicated for the management and prophylactic therapy of conditions such as atrial fibrillation and atrial flutter. In individuals with symptomatic atrial fibrillation or flutter, the treatment may be utilized to support the conversion of the heart's rhythm back to a normal sinus rhythm. It is also indicated for the suppression of recurrent, documented ventricular arrhythmias, particularly those deemed life-threatening by a clinician.

In addition to its cardiac uses, the medication is approved for a second therapeutic domain: it is indicated as an antimalarial agent for the treatment of uncomplicated Plasmodium falciparum malaria.

Eligibility and Restrictions for Use

The use of Kinidin (quinidine) is strictly defined by official regulatory documents, which establish specific populations who must not use the medicine due to significant health risks.

Populations for Whom Use is Contraindicated

Official labeling prohibits the use of Kinidin in individuals with:

  • Known Hypersensitivity: A history of allergic or severe immune-mediated reactions (such as thrombocytopenia or hepatitis) to quinidine, quinine, or related compounds.
  • Certain Heart Conditions: Specific cardiac conduction defects, including complete atrioventricular (AV) block without a functional pacemaker, a prolonged QT interval, or a clinical history of torsades de pointes.
  • Neuromuscular Disease: The presence of myasthenia gravis.
  • Uncorrected Electrolyte Imbalances: Abnormalities such as hypokalemia (low potassium) or hypomagnesemia (low magnesium), which must be corrected prior to initiation of therapy due to the increased risk of severe cardiac events.

Use in Specific Populations

Population Eligibility Status (Regulatory Basis)
Pediatric Has been used for abnormal heart rhythms and malaria, though not widely studied across all contexts.
Geriatric Permitted, but may require closer monitoring or lower doses due to potentially slower elimination from the body.
Pregnancy Use is advised only if the potential benefit justifies the risk.
Lactation Passes into breast milk; medical advice should be sought to determine if use is appropriate.
Organ Impairment Severe hepatic or renal impairment requires special consideration and risk assessment due to reduced drug clearance.

What should I know about interactions with other medicines?

Kinidin (quinidine) can interact with a wide range of medicinal products, primarily by influencing their concentration in the body or by having additive effects on the heart. Kinidin is an inhibitor of the cytochrome P450 enzyme CYP2D6, which means it can increase the plasma levels of many drugs that are metabolized by this enzyme, such as certain tricyclic antidepressants. Kinidin also inhibits the metabolism of some dihydropyridine calcium channel blockers (e.g., nifedipine), potentially requiring dosage adjustment for both medicines.

Simultaneous use with the cardiac glycoside digoxin can significantly slow the elimination of digoxin, potentially doubling its serum concentration; a reduction in digoxin dosage is usually necessary when these drugs are co-administered. Due to potential additive effects on heart rhythm, the combination of Kinidin with other drugs that prolong the QT interval is often avoided or requires careful monitoring. Furthermore, medicines that are strong CYP3A4 inducers (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine) can decrease Kinidin plasma levels, leading to loss of effectiveness. Conversely, CYP3A4 inhibitors (e.g., certain azole antifungals, macrolide antibiotics) can increase Kinidin levels, raising the risk of toxicity.

Mechanism of Action

Kinidin, which is the trade name for Quinidine, functions as a multiple ion channel inhibitor, with a primary action in cardiac tissue.

Its main biological target is the voltage-gated sodium channel ( Na v1.5), where it acts as a non-competitive inhibitor to block the fast inward sodium current ( I Na) during the initial depolarization phase (Phase 0) of the myocardial action potential. This interaction exhibits use-dependent block, intensifying at higher frequencies of cellular depolarization.

Simultaneously, Kinidin modulates repolarization by inhibiting several voltage-gated potassium channels, including the rapid ( I Kr) and slow ( I Ks) components of the delayed rectifier current, and the transient outward current ( I to). The cumulative inhibition of these outward potassium currents prolongs the action potential duration (APD) and the effective refractory period (ERP) of the cardiac myocyte. The downstream cascade of these ion current modulations is a systemic decrease in myocardial excitability and reduced impulse conduction velocity throughout the atria, ventricles, and His-Purkinje system.

Dosage and Administration Information

Kinidin (quinidine) is a prescription antiarrhythmic medication and should be taken exactly as prescribed by a healthcare provider. The dosage and schedule are highly individualized based on the specific condition being treated (such as atrial fibrillation or ventricular arrhythmias) and the drug formulation (immediate-release or extended-release).

Administration Guidelines

  • Dosage: Your physician will determine the precise dose. Immediate-release quinidine sulfate tablets are typically taken every 6 hours, while extended-release formulations (quinidine gluconate) are often administered every 8 to 12 hours. Do not take more or less than instructed, and maintain consistent dosing times each day.
  • With Food: Taking the tablet with food may help to minimize stomach upset.
  • Extended-Release Tablets: Swallow extended-release tablets whole. They should not be crushed, chewed, or broken, as this can affect the controlled release of the medication and may lead to a sudden increase in drug level. Some extended-release tablets may be scored and can be broken in half if specifically instructed by a doctor.

Important Considerations

  • Do Not Stop Suddenly: Discontinuing Kinidin abruptly can cause serious cardiac side effects, including a worsening of the underlying heart condition. Consult your doctor before making any changes to your regimen.
  • Monitoring: Due to the potential for serious cardiac effects, continuous monitoring of heart rhythm and function (via ECG) is often required when initiating or adjusting the dose, especially in patients with existing heart disease or risk factors.
  • Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Kinidin

Evidence for Use in Atrial Fibrillation and Atrial Flutter

Kinidin was studied for its use in managing heart rhythm, particularly in conditions characterized by fluctuating or episodic manifestations, such as Atrial Fibrillation (AF) and Atrial Flutter. Research in this area primarily involved Randomized Controlled Trials (RCTs) and meta-analyses. These studies explored how the medication affected the heart rhythm in adult patients who had experienced AF or Flutter.

The outcomes related to systemic or functional imbalance that were often measured included the rate at which the abnormal rhythm returned (recurrence) and major clinical outcomes such as all-cause mortality. The studies monitored patients over defined time intervals, and the research describes measurements of rhythm stability during those periods. However, older systematic reviews of these trials reported a pattern that was associated with higher all-cause mortality when compared to control groups, an observation noted in the regulatory evidence record. Research provides insight into short-term changes, but longer-term follow-up data remains less common.


Evidence for Use in Recurrent Ventricular Arrhythmias

This medication was also evaluated in studies exploring its potential role in conditions associated with acute or disruptive episodes, specifically recurrent ventricular arrhythmias (VAs). Research examined Kinidin in adult populations experiencing these VAs, and also in patients with specific, rare genetic conditions like Brugada Syndrome. These studies explored short-term symptom changes, with outcomes related to systemic or functional imbalance being measured, such as the frequency of documented VA episodes.

The findings describe measurements of VA episode frequency in some studies. Research explored its use for outcomes related to the management of sudden cardiac events in small groups of patients with specific genetic syndromes. However, much of the data available for general VA suppression is derived from older, historical clinical trials, and comparative evidence against more recently developed treatments is lacking.


Research Gaps and What Remains Uncertain

The evidence highlights what is known—and what is still uncertain—about Kinidin. Key limitations documented in the research include that certainty remains low due to several factors:

  • Evidence Quality Varies: The quality of available evidence is heterogeneous, with some data derived from older trials that do not reflect current medical practices or trial designs.
  • The Mortality Signal: The pattern observed in older studies indicating an association with higher all-cause mortality is an area of uncertainty within the broader evidence landscape.
  • Long-Term Data: There is limited information for long-term outcomes and chronic use, particularly concerning major event rates beyond the initial study period.

Key Studies & References

  1. Quinidine as an Antimalarial Agent: CDC/WHO Guidelines and Review
  2. MedlinePlus Drug Information: Quinidine

Frequently Asked Questions (FAQ)

Common questions about Kinidin (FAQ)


Q: What foods or drinks should be avoided when taking Kinidin?

A: Official information indicates that Kinidin is metabolized by specific liver enzymes (CYP3A4). Certain substances, most notably grapefruit juice, are known to interfere with this enzyme, which could potentially increase the amount of Kinidin in the blood. To manage the risk of side effects, it is important to clarify any necessary dietary restrictions with a healthcare provider.


Q: Can people with kidney problems take Kinidin?

A: Official guidance indicates that caution is necessary for individuals with renal impairment (kidney problems). Regulatory documents state that this population may eliminate the medication more slowly. Due to this slower clearance, this population typically requires careful monitoring and potential dose adjustments.


Q: How often is Kinidin usually prescribed to be taken per day?

A: The prescribed frequency is determined by the specific formulation used. Official labeling generally advises that immediate-release forms are typically taken four times daily. Extended-release forms are designed for sustained therapeutic levels and are often administered two or three times daily.


Q: Can Kinidin affect sleep patterns or cause insomnia?

A: Changes in sleep habits have been noted in product information as a potential side effect of quinidine. These effects are considered less common, but official documents note that sleep patterns could potentially be affected while taking the medication.


Q: Are there specific lab tests required before starting Kinidin?

A: Yes, specific monitoring is necessary due to the potential cardiac effects of the medication. Prior to and during treatment, official warnings advise frequent Electrocardiograms (ECG) to monitor heart rhythm. In addition, electrolyte levels (such as potassium and magnesium) must be monitored and addressed if abnormalities are detected.


Q: Can taking grapefruit or grapefruit juice interfere with Kinidin?

A: Yes, grapefruit juice is known to affect the liver enzyme (CYP3A4) that breaks down Kinidin. If the enzyme's function is affected, Kinidin levels in the bloodstream may be increased. This elevated concentration could lead to a greater risk of drug-related toxicity.


Q: Is Kinidin safe for children or adolescents?

A: Regulatory documents mention that the medication has been used in the pediatric population for certain heart rhythm issues. However, official information also notes that its use is not widely studied across all childhood contexts, and its appropriateness should be discussed with a specialist.


Q: Are there specific times of day that are better for taking Kinidin?

A: While the exact time of day for administration is individualized, official guidelines emphasize the importance of taking the medication at consistent dosing times each day. This practice helps ensure stable, therapeutic levels of the drug are maintained in the body.


Q: Can Kinidin interact with common supplements like magnesium or potassium?

A: Yes, there is an interaction concern. Official warnings state that low levels of electrolytes like potassium and magnesium must be corrected before starting Kinidin. Because these supplements can significantly affect these electrolyte balances, the use of such supplements necessitates careful review and monitoring by a healthcare provider.


Q: What are the signs of a severe allergic reaction to Kinidin?

A: According to official product information, a severe hypersensitivity reaction may present as symptoms like a widespread rash, fever, or joint pain. Furthermore, serious blood-related reactions, such as a severe drop in blood platelet levels (thrombocytopenia), have also been documented.


Q: Does Kinidin interact negatively with alcohol consumption?

A: Official information advises caution regarding alcohol consumption while taking Kinidin. Alcohol may worsen some of the medication's side effects, such as increasing feelings of dizziness or impairment in thinking and judgment.


Q: Do any common antibiotics interact with Kinidin?

A: Yes. Regulatory documents specifically highlight interactions with certain antibiotics. For example, some macrolide antibiotics (like erythromycin) can interfere with the breakdown of Kinidin in the liver. This can lead to an increase in Kinidin concentration, which may raise the risk of toxicity.


Q: Can Kinidin affect my driving ability or concentration?

A: Side effects of Kinidin, such as dizziness, lightheadedness, and blurred vision, are commonly reported. Since these effects can impair concentration and reflexes, regulatory precautions advise caution regarding activities like driving or operating machinery.


Q: Can Kinidin interact with herbal remedies or teas?

A: Official warnings advise caution, as Kinidin is known to interact with a wide range of medicinal products. This includes certain herbal supplements and remedies that could affect the same liver enzymes or electrolyte balance pathways as the drug, necessitating a physician's review.

How should Kinidin be stored and disposed of?

How to Store and Dispose of Kinidin?

Kinidin (quinidine) must be stored and handled under specific conditions defined by regulatory documents to preserve its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, and protected from light and moisture.
Safety The medication must be kept strictly out of the sight and reach of children.

️ Disposal Instructions

Disposal of unused or expired Kinidin must follow pharmaceutical waste guidelines. Regulators recommend using a drug take-back program as the preferred method for discarding the medicine. The product must not be thrown away via wastewater or flushed down the toilet, to prevent environmental contamination. If a take-back program is unavailable, dispose of solid forms in household trash by mixing with an unappealing substance, securing it in a sealed bag, and then discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Kinidin found in:

A-Z Index: